Patient

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Retrieved on: 
Wednesday, January 19, 2022 - 9:49pm
Survival, Trial of the century, American Society of Clinical Oncology, Patient, Technology, Antigen, Clinical trial, Orphan Drug Act of 1983, Degenerative disease, Population, Toxic epidermal necrolysis, NASDAQ, Marker, CEO, GLOBE, Baylor College of Medicine, AML, Society, IND, Pancreatic cancer, WT1, Lymphatic system, Marketing, Therapy, Company, United, Orphan drug, ASCO, Cancer, Neoplasm, Blood, PRAME, FDA, TCR, SSX2, Baylor University, NY-ESO-1, Pharmaceutical industry, Vaccine, Survivin

The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.

Key Points: 
  • The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.
  • Marker developed MT-601, a new product targeting six tumor-associated antigens (PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, WT1) highly expressed in pancreatic cancer.
  • The Company plans to file an Investigational New Drug Application (IND) for MT-601 for the treatment of pancreatic cancer in 2022.
  • The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.

Treace Announces Grant of U.S. Patent on Instrumented Bunion Correction

Retrieved on: 
Wednesday, January 19, 2022 - 9:15pm
Patient, Foot, United States Patent and Trademark Office, Bunion, Patent, CEO, GLOBE, Company, 3D printing, Pharmaceutical industry, TREAC

The patent, granted earlier this month, augments Treaces extensive and growing patent portfolio covering instrumented bunion correction.

Key Points: 
  • The patent, granted earlier this month, augments Treaces extensive and growing patent portfolio covering instrumented bunion correction.
  • We are pleased that the Patent Office continues to recognize the novel advances made by Treace.
  • The addition of this recent patent grant further strengthens our intellectual property position and highlights our commitment to innovation in advancing the surgical treatment of bunion patients, said John T. Treace, CEO, Founder and Board Member of Treace.
  • Treace recently expanded its offering with the Adductoplasty Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

Retrieved on: 
Wednesday, January 19, 2022 - 9:59pm
Legal, Professional Services, Telephone, Patient, News, Dark Enlightenment, Suite, COVID-19, NASDAQ, Aviptadil, Emergency Use Authorization, Food and Drug Administration, Pharmaceutical industry

Law Offices of Howard G. Smith announces an investigation on behalf of NRx Pharmaceuticals, Inc. (NRx or the Company) (NASDAQ: NRXP ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of NRx Pharmaceuticals, Inc. (NRx or the Company) (NASDAQ: NRXP ) investors concerning the Companys possible violations of the federal securities laws.
  • In June 2021, NRx announced that it filed an application with U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients suffering with respiratory failure.
  • On this news, NRxs stock fell $2.27, or 25.5%, to close at $6.65 per share on November 5, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022

Retrieved on: 
Wednesday, January 19, 2022 - 9:15pm
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, People, Forward-looking statement, Patient, ACE2, CD47, Cholangiocarcinoma, HER2, Conjugation, Biotechnology, MET, BTC, COVID-19, Board of directors, Inc., Severe acute respiratory syndrome coronavirus 2, CMO, COO, NYSE, Safety, ESMO, Completeness, Intellectual property, IND, Â, Review, Leadership, VP, Time, Private Securities Litigation Reform Act, Research and development, Company, United, Drug development, Q4, Workforce, Twitter, GEA, Engineering, Chair, Partnership, Board, Investment, Fine chemical, Management, Renewable energy, Medical imaging, Medicine, Pharmaceutical industry, Bank, Research, Pfizer, BeiGene, Zymeworks

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
  • These measures, including the reduction in our workforce announced today, provide opportunities to reduce our future planned expenditures while continuing to fund our key priorities for 2022 and 2023.
  • The Company intends to report full Q4 and FY 2021 results and provide any further corporate updates on February 24, 2022.
  • Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection

Retrieved on: 
Wednesday, January 19, 2022 - 10:01pm
FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Patient, File, Private Securities Litigation Reform Act, SEC, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, David Berry (inventor), Yale School of Medicine, Spore, The New England Journal of Medicine, Safety, Growth, NEJM, Breakthrough therapy, Firmicutes, Disease, Variometer, Graft-versus-host disease, AGAF, Recurrence, CDI, Ulcerative colitis, U.S. Securities and Exchange Commission, Nasdaq, Tissue, Clostridioides difficile infection, Therapy, FACG, Orphan drug, Subclinical infection, Quality of life, MD, Risk, Food, FDA, Security (finance), Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI).
  • The SER-109 ECOSPOR III Phase 3 study ( ClinicalTrials.gov identifier: NCT03183128) was a multicenter, randomized, placebo-controlled study.
  • In May 2021, Seres presented 24-week clinical data from the study that demonstrated significantly reduced recurrence rates compared to placebo.
  • The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

Encompass Health Corporation Announces Plan to Spin Off Home Health and Hospice Business under the New Brand Enhabit Home Health & Hospice

Retrieved on: 
Wednesday, January 19, 2022 - 9:15pm
Patient, EHC, Annual report, Intention, Encompass Health, Private Securities Litigation Reform Act, Newsroom, SEC, Form 10-K, COVID-19, Hospice, NYSE, Wachtell, Lipton, Rosen & Katz, Fortune, Instagram, HH, Industry, Director, Company, Goldman Sachs, Twitter, Encompass, Hospital, IRS, Policy, Facebook

The spin-off, which is expected to be tax-free to Encompass Health's shareholders, will result in Encompass Health's shareholders owning stock in both companies.

Key Points: 
  • The spin-off, which is expected to be tax-free to Encompass Health's shareholders, will result in Encompass Health's shareholders owning stock in both companies.
  • The establishment of Enhabit Home Health & Hospice will furtherstrengthenEnhabit's focus on high-quality, cost-effective care delivered in the home setting.Enhabit Home Health & Hospice chose the name Enhabit because it intuitively is linked to the home.
  • In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein.
  • No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions.

Vohra Wound Physicians Awarded Grant by Kentucky's Cabinet for Health and Family Services to Certify 150 Nurses in Wound Care

Retrieved on: 
Wednesday, January 19, 2022 - 9:00pm
Patient, Nursing, Cabinet, LDS Family Services, GLOBE, CNE, Health, Office of Inspector General, U.S. Department of Health and Human Services, Program, Certification, Vohra, Child, Fraud, Physician, Medicine

FRANKFORT, Ky., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vohra Wound Care has been awarded a grant by Kentucky's Cabinet for Health and Family Services.

Key Points: 
  • FRANKFORT, Ky., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vohra Wound Care has been awarded a grant by Kentucky's Cabinet for Health and Family Services.
  • The funding provides support for 150 nurses to become certified in wound care through the Vohra Wound Care Nurse certification program.
  • Nurses from eligible facilities who complete this program will be awarded the credential of VWCN, an industry-leading certification specific to wound care of the nursing home resident.
  • Based on over 20 years of experience caring for patients in nursing homes, Vohra Wound Physicians created this wound care certification program.

National Headache Foundation Position Statement on the Treatment of Migraine

Retrieved on: 
Wednesday, January 19, 2022 - 8:13pm
Disability, Education, Awareness, Research, Patient, Vertigo, HCU, Dizziness, Phonophobia, Standing, Migraine, Human, Population, Contraindication, NHF, Nausea, ER, Neutralizing antibody, Weight gain, Disease, Tolerability, GLOBE, Language, Positive statement, Headache, Goal, Tremor, Pain, Heart, Tinnitus, Work, Bradycardia, Risk, CGRP, Topiramate, FDA, Chronic kidney disease, Practitioner, Vomiting, Photophobia, Pharmaceutical industry, Health insurance, Medicine, Risk management, Residential care

Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.

Key Points: 
  • Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.
  • Unfortunately, the current care models adopted by payers (health insurance) have not kept pace with the many advances in treatment.
  • The vision of the National Headache Foundation (NHF) is a world without headache.
  • In the future, NHF will expand upon this Position Statement and propose specific treatment guidelines.

Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico

Retrieved on: 
Wednesday, January 19, 2022 - 7:26pm
Forward-looking statement, Patient, SAN, Vaccine, Private Securities Litigation Reform Act, Antibody, PHN, Sciatica, CEO, Autoimmune disease, Trigeminal neuralgia, GLOBE, U.S. Securities and Exchange Commission, RTX, Industry, Pain, Therapy, Sale, Cancer, TRPV1, FDA, Osteoarthritis, Security (finance), Omicron, Risk, Annual report, Pharmaceutical industry, Generic drug, COVID-19

Sorrento Therapeutics Mexico (Sorrento Mexico) distributed last week approximately one million COVISTIX tests in Mexico.

Key Points: 
  • Sorrento Therapeutics Mexico (Sorrento Mexico) distributed last week approximately one million COVISTIX tests in Mexico.
  • Additional millions of COVISTIX tests are scheduled to be delivered to meet the ever-growing demand in Mexico.
  • SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that approximately 1,000,000 COVISTIX tests were distributed last week in Mexico.
  • Millions of additional COVISTIX tests are scheduled to be delivered to Mexico, with tens of millions more being manufactured to support the increasing demand for COVISTIX worldwide.

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Wednesday, January 19, 2022 - 9:05pm
IC50, Patient, KNTE, MBBS, Gastrointestinal cancer, SAN, FGFR, Clinical trial, Cholangiocarcinoma, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, FGFR2, Growth, EC50, HIV disease progression rates, Poster, GLOBE, Â, Cancer, FGFR1, Translational medicine, U.S. Securities and Exchange Commission, Nasdaq, Industry, Program, FGFR3, Therapy, Food, Immortalised cell line, ASCO, Investigational New Drug, FGFR4, Security (finance), Fibroblast growth factor receptor, Risk, ICC, Pharmaceutical industry

These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.

Key Points: 
  • These findings will be presented during a poster session at the ASCO Gastrointestinal Cancers Symposium taking place in San Francisco, January 20-22, 2022.
  • Oncogenic FGFR (FGFR1, FGFR2, FGFR3, and FGFR4) gene alterations are observed in approximately 7% of all human cancers.
  • KIN-3248 has been evaluated across wild-type FGFR family members and clinically relevant fusions and kinase domain resistance mutations in vitro.
  • Additional information on the ASCO GI Cancers Symposium is available through the conference website at: https://conferences.asco.org/gi .